You are not logged in.
Please login to continue selecting trials.
Trial Information
Generic NameRisperidoneProduct NameRISPERDAL®Therapeutic AreaNervous SystemProduct ClassPsycholepticsPharmacological SubgroupAntipsychoticsChemical SubgroupOther AntipsychoticsCondition StudiedSchizophrenia
Sponsor Protocol NumberRIS-SCH-302/CR003370Enrollment160Data PartnerJohnson & Johnson% Female36.0%Mean/Median Age (Years)16.0% White53.0%
Supporting Documentation
- Collected Datasets Available
- Data Definition Specification Available
- Protocol with Amendments Available
- Statistical Analysis Plan Available
- Clinical Study Report Available
Approved Data Requests Associated with this Trial
- 2025-0900 : Individual prediction of placebo response in acute psychosis trials
- 2025-0836 : rEVealIng Drug Effects when applyiNg psychomeTrics In schizophreniA triaLs (EVIDENTIAL)
- 2025-0740 : Trajectories of Relapse and Predictors of Functioning in Antipsychotic Clinical Trials
- 2025-0568 : Antipsychotic-Induced Negative Symptoms in Individuals with Schizophrenia: An Individual Participant Data Meta-Analysis of RCTs
- 2025-0352 : ALL-EMBRACED: clinicAL triaLs web-sErvice to Modify eligiBility cRiteria and pre-screening viA artifiCial intElligence methoDs
- 2024-0608 : Understanding treatment effects and symptom dynamics in schizophrenia using network analysis
- 2024-0280 : Individual-level and study-level predictors of placebo response and dropout in Schizophrenia Disorder clinical trials
- 2024-0272 : An evaluation of lack of early improvement and later non-response in early-onset schizophrenia: a systematic review and diagnostic test accuracy meta-analysis of data from randomized controlled trials.
- 2024-0008 : Sex differences in antipsychotic efficacy and side-effects in adults with acute exacerbations of schizophrenia: an individual-participant network meta-analysis
- 2022-4992 : Temporal trajectories of side-effects associated with antipsychotic treatment: An individual participant data meta-analysis
- 2021-4754 : Harnessing clinical trial data to inform real-world clinical decision making in the treatment of schizophrenia
- 2021-4575 : A Novel Method to Summarize Safety in Clinical Trials Using Pharmacological Class-Related Risks in FAERS
- 2019-3978 : Safety of Risperidone and Paliperdone in schizophrenia and bipolar disorder diagnosed patients - a systematic review and meta-analysis
- 2019-3958 : Machine Learning for predicting treatment efficacy and clinical categorizations across mental health disorders.
- 2019-3941 : Factors moderating estimates of antipsychotic efficacy in schizophrenia
- 2019-3827 : Prediction of outcome and adverse events in antipsychotic treatment
- 2017-1846 : Discontinuation symptoms in antipsychotics: Individual patient level analyses of randomized controlled trials
- 2017-1676 : Placebo Effects in Schizophrenia
- 2016-0880 : Incidence of death and other SAEs related to second generation antipsychotic or placebo treatment in RCTs - a systematic review and meta-analysis
